Combined Company Positioned to Offer Best-in-Class and Innovative Drug Discovery Solutions
RUTHERFORD, NJ and MAPLE GROVE, MN, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the Company) (Nasdaq: CGIX), and StemoniX, Inc., today announced the entry into a definitive merger agreement. Cancer Genetics is a leader in drug discovery and preclinical oncology and immuno-oncology services. StemoniX, a privatecompany, isa leader in developing high-throughput disease-specifichuman organoid platforms integrated withleading-edge data science technologies. Under the terms of the merger agreement, StemoniX will merge with a newly formed subsidiary of Cancer Genetics in an all-equity transaction. Upon shareholder approval, the combined company expects to remain listed on the Nasdaq Stock Market. StemoniX will retain its name and become a wholly-owned subsidiary of Cancer Genetics.
The transaction will position the combined company to harness the synergies between two critical modalities of drug discovery and development - advanced animal models and relevant human high-throughput organoid platforms. The resulting integration of scientific and technology-based expertise, skilled management teams, and ability to offer customers an end-to-end platform will de-risk and accelerate development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the combined company. In combination, Cancer Genetics and StemoniX currently enjoy partnerships and R&D relationships with dozens of global pharmaceutical and biotechnology companies.
"The process of discovering and developing a new drug candidate takes years and comes with a price tag of hundreds of millions - or even billions - of dollars. However, we are at unique time in the drug discovery industry as the convergence of technological innovations in both biology and software will transform conventional workflows in time and accuracy. To convert the time-consuming and labor-intensive process of developing a drug for market, we now look to supplement traditional discovery and drug approval mechanisms to include humanized cell-based assays with artificial intelligence (AI) along with our core vivoPharm business. Given that our strategy and approach are strongly aligned with those of StemoniX, we are pleased to have moved forward with this proposed transaction," stated Jay Roberts, Chief Executive Officer of Cancer Genetics.
The pharma industry and society are at a critical pivot point. Viral pandemics and diseases lacking treatments require a new way of innovation. The proposed merger expects to expand our ability to engage with a larger audience of potential partners and expand our internal capabilities as we deliver on our mission to rapidly discover the safest and most effective therapeutics on behalf of our partners and our shareholders. The mission will stay consistent - allow scientists to quickly and economically conduct high-throughput toxicity and drug development studies in ready-to-assay plates containing functional microOrgans, stated Ping Yeh, Chief Executive Officer of StemoniX.
ABOUT THE TRANSACTION
Pursuant to the merger agreement, Cancer Genetics will acquire all of the outstanding capital stock of StemoniX in exchange for a number of shares of its common stock which will represent approximately 78% of the outstanding common stock of Cancer Genetics, subject to certain adjustments and prior to the effects of the financing referred to below, with the current equity holders of Cancer Genetics retaining 22% of the common stock immediately following the consummation of the merger.
The Boards of Directors of both companies have approved the proposed merger, which is expected to close in the fourth quarter of 2020, subject to the approval of the shareholders of both Cancer Genetics and StemoniX, financing and other customary closing conditions.
H.C. Wainwright & Co. is acting as financial advisors to the Board of Directors of Cancer Genetics, and Lowenstein Sandler is acting as its legal counsel. Northland Securities, Inc. is acting as financial advisor to the Board of Directors of StemoniX and Taft, Stettinius & Hollister is acting as its legal counsel.
ABOUT CANCER GENETICS
Through its vivoPharm subsidiary, Cancer Genetics offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies and academic research centers. The Company is focused on precision and translational medicine to drive drug discovery and novel therapies. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities. For more information, please visit http://www.cancergenetics.com.
ABOUT STEMONIX, INC.
StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPSC) cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom human iPSC disease models at large scale for high-throughput screening. With leading-edge iPSC technologies and data science, StemoniX is helping global institutions bring the most promising medicines to patients. To learn more about how StemoniX products and services are accelerating discoveries, please visit http://www.StemoniX.com.
For more information, please visit or follow CGI at:
Twitter: @Cancer_Genetics
And StemoniX at:
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.s expectations regarding satisfaction of closing conditions, consummation of the merger, future financial and/or operating results, and potential for our services, future revenues or growth in this press release constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as will, believes, plans, anticipates, expects, estimates) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our ability to satisfy all closing conditions to the merger, our attempts to adapt to the global coronavirus pandemic, achieve profitability by increasing sales of our pre-clinical services, maintain our existing customer base and avoid cancellation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs and conditions to the merger, properly evaluate strategic options, and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2019 and Form 10-Q for the quarter ended June 30, 2020, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
Investor Contacts:Jennifer K. Zimmons. Ph.D.Investor RelationsZimmons International Communications, Inc.Email: jzimmons@zimmonsic.comPhone: +1.917.214.3514
More:
Cancer Genetics and StemoniX Sign Definitive Agreement to Merge - GlobeNewswire
- Genetic Discrimination Is Coming for Us All - The Atlantic - November 16th, 2024
- Family connection: Genetics of suicide - WNEM - November 16th, 2024
- Study links heart shape to genetic risk of cardiovascular diseases - News-Medical.Net - November 16th, 2024
- Genetic architecture of cerebrospinal fluid and brain metabolite levels and the genetic colocalization of metabolites with human traits - Nature.com - November 16th, 2024
- Genetic connectivity of wolverines in western North America - Nature.com - November 16th, 2024
- Toward GDPR compliance with the Helmholtz Munich genotype imputation server - Nature.com - November 16th, 2024
- Leveraging genetic variations for more effective cancer therapies - News-Medical.Net - November 16th, 2024
- Bringing precision to the murky debate on fish oil - University of Arizona News - November 16th, 2024
- International experts gathered in Tashkent to tackle rare disease for Uzbekistan - EurekAlert - November 16th, 2024
- Mercys Story: Living life with 22q, a genetic condition - WECT - November 16th, 2024
- Cold case with ties to Houghton County solved through genetic genealogy after 65 years - WLUC - November 16th, 2024
- 23andMe customer? Here's what to know about the privacy of your genetic data. - CBS News - November 16th, 2024
- Single-cell RNA analysis finds possible genetic drivers of bone cancer - Illumina - November 16th, 2024
- Multi-trait association analysis reveals shared genetic loci between Alzheimers disease and cardiovascular traits - Nature.com - November 16th, 2024
- With 23andMe Struck by Layoffs, Can You Delete Genetic Data? Here's What We Know - CNET - November 16th, 2024
- Genetic testing firm 23andMe cuts 40% of its workforce amid financial struggles - The Guardian - November 16th, 2024
- Genetic study solves the mystery of 'selfish' B chromosomes in rye - Phys.org - November 16th, 2024
- Genetic changes linked to testicular cancer offer fresh insights into the disease - Medical Xpress - November 16th, 2024
- Eating less and genetics help you to live longer, but which factor carries the most weight? - Surinenglish.com - November 16th, 2024
- We must use genetic technologies now to avert the coming food crisis - New Scientist - November 16th, 2024
- NHS England to screen 100,000 babies for more than 200 genetic conditions - The Guardian - October 6th, 2024
- Largest-ever genetic study of epilepsy finds possible therapeutic targets - Medical Xpress - October 6th, 2024
- 23andMe is on the brink. What happens to all its DNA data? - NPR - October 6th, 2024
- The mountains where Neanderthals forever changed human genetics - Big Think - October 6th, 2024
- Gene Activity in Depression Linked to Immune System and Inflammation - Neuroscience News - October 6th, 2024
- Integrative multi-omics analysis reveals genetic and heterotic contributions to male fertility and yield in potato - Nature.com - October 6th, 2024
- Genetic and non-genetic HLA disruption is widespread in lung and breast tumors - Nature.com - October 6th, 2024
- Aneuploidy as a driver of human cancer - Nature.com - October 6th, 2024
- Myriad Genetics and Ultima Genomics to Explore the UG - GlobeNewswire - October 6th, 2024
- Biallelic and monoallelic variants in EFEMP1 can cause a severe and distinct subtype of heritable connective tissue disorder - Nature.com - October 6th, 2024
- Genetic and clinical correlates of two neuroanatomical AI dimensions in the Alzheimers disease continuum - Nature.com - October 6th, 2024
- Cracking the Genetic Code on Facial Features - DISCOVER Magazine - October 6th, 2024
- Ancestry vs. 23andMe: How to Pick the Best DNA Testing Kit for You - CNET - October 6th, 2024
- The Mercedes-AMG C63 is bold, but beholden to its genetics - Newsweek - October 6th, 2024
- The Austin Chronic: Texas A&Ms Hemp Breeding Program Adds Drought-Resistant Genetics to the National Collection - Austin Chronicle - October 6th, 2024
- Genetics and AI Help Patients with Early Detection of Breast Cancer Risk - Adventist Review - October 6th, 2024
- 23andMe Is Sinking Fast. Can the Company Survive? - WIRED - October 6th, 2024
- Genetic variations in remote UK regions linked to higher disease risk - Medical Xpress - October 6th, 2024
- Comprehensive mapping of genetic activity brings hope to patients with chronic pain - Medical Xpress - October 6th, 2024
- Genetics - Definition, History and Impact | Biology Dictionary - June 2nd, 2024
- Gene | Definition, Structure, Expression, & Facts | Britannica - June 2nd, 2024
- Raha Kapoor's blue eyes remind fans of her great-grandfather, Raj Kapoor; here's what genetics says - IndiaTimes - December 30th, 2023
- Human genetics | Description, Chromosomes, & Inheritance - December 13th, 2023
- BASIC GENETICS INFORMATION - Understanding Genetics - NCBI Bookshelf - December 13th, 2023
- Introduction to Genetics - Open Textbook Library - December 13th, 2023
- "When them genetics kick in its all over" - NBA fans send in rib-tickling reactions as LeBron James attends Zhuri James' volleyball game -... - October 16th, 2023
- David Liu, chemist: We now have the technology to correct misspellings in our DNA that cause known genetic diseases - EL PAS USA - April 7th, 2023
- World Health Day 2023: Understanding the science of Epi-genetics and how to apply it in our daily lives - Free Press Journal - April 7th, 2023
- Genetics - National Institute of General Medical Sciences (NIGMS) - March 29th, 2023
- GENETICS 101 - Understanding Genetics - NCBI Bookshelf - March 29th, 2023
- People always think Im skinny because of good genetics theyre shocked when they see what I used to lo... - The US Sun - March 29th, 2023
- Forensics expert explains 'genetic genealogy' process believed to be used in Kohberger's arrest - KTVB.com - January 6th, 2023
- Idaho student murders: What is genetic genealogy, a tool reportedly used to help capture the suspect? - FOX 10 News Phoenix - January 6th, 2023
- What is a Genetic Counselor and How Can They Help You Navigate Your Healthcare Journey? - ABC4.com - December 3rd, 2022
- Ancient Art and Genetics Reveal Origin of World's Most Expensive Spice - The Wire Science - June 26th, 2022
- Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration - GlobeNewswire - June 26th, 2022
- Obesity and genetics: Expert shares insights - Hindustan Times - June 26th, 2022
- Researchers discover genetic variants that increase Alzheimer's risk - WCVB Boston - June 26th, 2022
- Where science meets fiction: the dark history of eugenics - The Guardian - June 26th, 2022
- Clinical Conference: A Discussion with BASE10 Genetics - Skilled Nursing News - June 26th, 2022
- Genetics Really Said Copy And Paste: People Are Amazed At How Similar This Woman Looks To Her Dad In These 5 Recreation Photos - Bored Panda - June 26th, 2022
- 49 Genetic Variants That Increase the Risk of Varicose Veins Identified - Technology Networks - June 26th, 2022
- Genetic relationships and genome selection signatures between soybean cultivars from Brazil and United States after decades of breeding | Scientific... - June 26th, 2022
- Earlham woman loses weight with ChiroThin after her own doctor told her "genetics" wouldn't allow that to happen | Paid Content - Local 5 -... - June 26th, 2022
- Science and genetics used to boost Fernside farm - New Zealand Herald - June 26th, 2022
- Genetics-based guidelines to buying a bull at an auction - Farmer's Weekly SA - June 26th, 2022
- Polio: we're developing a safer vaccine that uses no genetic material from the virus - The Conversation - June 26th, 2022
- 7 lifestyle habits which can halve your risk of dementia - World Economic Forum - June 26th, 2022
- Addressing the 'Trust Factor': South Carolina Researchers Tackle Health Disparities Using Genetics - Physician's Weekly - June 8th, 2022
- Dumb luck, genetics? Why have some people never caught COVID-19? | Daily Sabah - Daily Sabah - June 8th, 2022
- Genetics Breakthrough in Sea Urchins to Aid in Biomedical Research - Scripps Institution of Oceanography - June 8th, 2022
- Genetic Control Of Autoimmune Disease Mapped To Cellular Level - Bio-IT World - June 8th, 2022
- Bazelet to Supply Its Federally Legal Cannabis Genetics to DEA Approved Research Entities for Rigorous Scientific Research on the Clinical Effects of... - June 8th, 2022
- Alameda County Awaits Key Decision Regarding The Use of Genetic Testing in Asbestos Cases - JD Supra - June 8th, 2022
- Diversity in Genetic Research Is Key to Enhancing Treatment of Chronic Diseases in Africa - Technology Networks - June 8th, 2022
- CSU partners with American Hereford Association on genetics research - Beef Magazine - June 8th, 2022
- Unraveling the Tangled History of Polar Bears to Brown Bears Using Genetic Sequencing - Nature World News - June 8th, 2022
- Did My Lifestyle or Genetics Cause ATTR-CM? Learning More About This Heart Condition That Often Goes Misdiagnosed - SurvivorNet - June 8th, 2022
- Your genes affect your education. Here's why that's controversial. - Big Think - June 8th, 2022
- Study mines cancer genetics to help with targeted treatment - ABC News - April 26th, 2022